Overview

A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole

Status:
Completed
Trial end date:
2021-03-08
Target enrollment:
0
Participant gender:
All
Summary
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214-02 to Rabeprazole in healthy volunteers.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Addpharma Inc.
Treatments:
Rabeprazole
Criteria
Inclusion Criteria:

- Age 19~50 years in healthy volunteers

- BMI is more than 18.0 kg/m^2 , no more than 27.0 kg/m^2

- Subjects who have ability to comprehend the objectives, contents of study and property
of study drug before participating in trial and have willingness to sign of informed
consent in writing

Exclusion Criteria:

- Presence of medical history or a concurrent disease that may interfere with treatment
and safety assessment or completion of this clinical study, including clinically
significant disorders in digestive system, neuropsychiatric system, endocrine system,
liver, cardiovascular system

- Subjects who judged ineligible by the investigator